Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875229 | 0.88 | KDM4E (0.51) | KDM4ELMNATP53L3MBTL1ALOX5 | |
| SCHEMBL29068747 | 0.86 | KDM4E (0.50) | KDM4ELMNATP53L3MBTL1ALOX5 | |
| SCHEMBL6470774 | 0.83 | FLT3 (0.47) | KDM4ELMNATP53L3MBTL1ALOX5 | |
| SCHEMBL6586200 | 0.81 | KDM4E (0.50) | KDM4ELMNATP53L3MBTL1ALOX5 | |
| SCHEMBL3836490 | 0.79 | FLT3 (0.50) | KDM4ELMNATP53L3MBTL1ALOX5 | |
| SCHEMBL4265956 | 0.79 | PDGFRB (0.56) | KDM4ELMNATP53L3MBTL1FLT3 | |
| SCHEMBL30073611 | 0.79 | PDGFRB (0.56) | KDM4ELMNATP53L3MBTL1FLT3 | |
| SCHEMBL8358119 | 0.77 | KDM4E (0.44) | KDM4ELMNATP53L3MBTL1TAS1R3 | |
| SCHEMBL1833251 | 0.77 | KDM4E (0.55) | KDM4ELMNATP53L3MBTL1FLT3 | |
| SCHEMBL5260106 | 0.77 | KDM4E (0.48) | KDM4ELMNATP53L3MBTL1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-3921331-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020160685-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2020-08-13 | — | — | WO | disclosed |
| US-8071552-B2 | Peptides and peptidomimetics binding to CD23 | UNIVERSITE BORDEAUX 2 (FR) | 2011-12-06 | — | — | US | disclosed |
| EP-1733231-B1 | PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 | UNIV BORDEAUX 2 (FR) | 2011-05-04 | — | — | EP | disclosed |
| US-20080039402-A1 | Peptides and Peptidomimetics Binding to Cd23 | UNIVERSITE BORDEAUX 2 | 2008-02-14 | — | — | US | disclosed |
| EP-1733231-A2 | PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 | Université Bordeaux 2 (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005098435-A2 | PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 | UNIVERSITE BORDEAUX 2 (FR) | 2005-10-20 | — | — | WO | disclosed |
| EP-1313736-B1 | CONDENSED PYRAZINDIONE DERIVATIVES AS INHIBITORS OF PDE5 | LILLY ICOS LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6903099-B2 | Condensed pyrazindione derivatives | LILLY ICOS LLC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030181457-A1 | Chemical compounds | LILLY ICOS LLC | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181457-A1 | Chemical compounds | ABCG2, SDHA, CYP11B1 | KDM4E 4466/4885LMNA 1866/4885TP53 94/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | KDM4E 4644/4885LMNA 2483/4885TP53 4858/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | KDM4E 4644/4885LMNA 2483/4885TP53 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.